Genmab

GMAB · Nasdaq Copenhagen · DKK

2.343,00 kr+1,12 %+26,00 kr

Schlusskurs · 30. September 2026

Aktuelle Nachrichten

Schlagzeilen in der Originalsprache der Quelle.

Major Shareholder Announcement (öffnet in neuem Tab)
GlobeNewswire · 02.10.2026
Genmab Eyes Three Pivotal Phase III Cancer Readouts in Q4 (öffnet in neuem Tab)
27.09.2026
Grant of Restricted Stock Units and Warrants to Employees in Genmab (öffnet in neuem Tab)
24.09.2026
Genmab (CPSE:GMAB) Stock Sees Modest Fair Value Cut As Analysts Weigh Pipeline Risks (öffnet in neuem Tab)
24.09.2026
Notice to Convene an Extraordinary General Meeting of Genmab A/S (öffnet in neuem Tab)
08.09.2026
Could Genmab (GMAB) Stock Win as Royalty Growth Fuels a New Earnings Cycle? (öffnet in neuem Tab)
26.08.2026
Genmab to Participate in Upcoming Investor Conferences (öffnet in neuem Tab)
25.08.2026
Could AbbVie Inc. (ABBV) Win as Genmab A/S (GMAB) Faces a New Regulatory Test for Epcoritamab? (öffnet in neuem Tab)
13.08.2026
Here Are Wednesday’s Top Wall Street Analyst Research Calls: The Gap, Genmab, Hilton Worldwide, Intuitive Surgical, Marriott International, Merck, Novo Nordisk, Okta, and More (öffnet in neuem Tab)
12.08.2026
Genmab Stock Rises 4.4% as Drug Royalties Lift Outlook (öffnet in neuem Tab)
07.08.2026
Genmab (GMAB) Q2 2026 Earnings Call Transcript (öffnet in neuem Tab)
07.08.2026
Genmab AS (GMAB) (Q2 2026) Earnings Call Highlights: Strong Revenue Growth and Strategic ... (öffnet in neuem Tab)
06.08.2026
Genmab A/S Q2 Earnings Call Highlights (öffnet in neuem Tab)
06.08.2026
Genmab shares jump 8% after upbeat results prompt 2026 outlook raise (öffnet in neuem Tab)
06.08.2026
Genmab Announces Financial Results for the First Half of 2026 (öffnet in neuem Tab)
06.08.2026
Head and Neck Squamous Cell Carcinoma Market is Projected to Boost at a CAGR of 10.5% During the Forecast Period (2026–2036) Due to the Launch of Emerging Novel Immunotherapies | DelveInsight (öffnet in neuem Tab)
13.07.2026
Is Genmab A/S (GMAB) Stock Undervalued After Positive Epkinly DLBCL Trial Results? (öffnet in neuem Tab)
Insider Monkey · 08.07.2026
Genmab Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma (öffnet in neuem Tab)
GlobeNewswire · 06.07.2026
Genmab Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Demonstrating Statistically Significant Improvement in Progression-Free Survival (öffnet in neuem Tab)
Business Wire · 29.06.2026
Capital Increase in Genmab as a Result of Employee Warrant Exercise (öffnet in neuem Tab)
GlobeNewswire · 16.06.2026
Genmab’s EPCORE Data Deepens Lymphoma Profile As Investors Weigh Upside (öffnet in neuem Tab)
Simply Wall St. · 15.06.2026
Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) (öffnet in neuem Tab)
GlobeNewswire · 13.06.2026
Genmab Presents EPCORE® FL-1 Subgroup Data Demonstrating Consistent Efficacy and Safety Results for Epcoritamab in Combination with Rituximab and Lenalidomide (R2) Across Relapsed or Refractory (R/R) Follicular Lymphoma (FL) Patients (öffnet in neuem Tab)
Business Wire · 11.06.2026
Genmab Presents EPCORE® FL-1 Subgroup Data Demonstrating Consistent Efficacy and Safety Results for Epcoritamab in Combination with Rituximab and Lenalidomide (R2) Across Relapsed or Refractory (R/R) Follicular Lymphoma (FL) Patients (öffnet in neuem Tab)
GlobeNewswire · 11.06.2026